These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 7529804

  • 1. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis.
    Mohan C, Shi Y, Laman JD, Datta SK.
    J Immunol; 1995 Feb 01; 154(3):1470-80. PubMed ID: 7529804
    [Abstract] [Full Text] [Related]

  • 2. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells.
    Kaliyaperumal A, Michaels MA, Datta SK.
    J Immunol; 1999 May 15; 162(10):5775-83. PubMed ID: 10229810
    [Abstract] [Full Text] [Related]

  • 3. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
    Early GS, Zhao W, Burns CM.
    J Immunol; 1996 Oct 01; 157(7):3159-64. PubMed ID: 8816428
    [Abstract] [Full Text] [Related]

  • 4. CD4+ T cell lines with selective patterns of autoreactivity as well as CD4- CD8- T helper cell lines augment the production of idiotypes shared by pathogenic anti-DNA autoantibodies in the NZB x SWR model of lupus nephritis.
    Sainis K, Datta SK.
    J Immunol; 1988 Apr 01; 140(7):2215-24. PubMed ID: 2965184
    [Abstract] [Full Text] [Related]

  • 5. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function.
    Kalled SL, Cutler AH, Datta SK, Thomas DW.
    J Immunol; 1998 Mar 01; 160(5):2158-65. PubMed ID: 9498753
    [Abstract] [Full Text] [Related]

  • 6. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.
    Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D.
    J Immunol; 1997 Oct 01; 159(7):3104-8. PubMed ID: 9317105
    [Abstract] [Full Text] [Related]

  • 7. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus.
    Lajaunias F, Ida A, Kikuchi S, Fossati-Jimack L, Martinez-Soria E, Moll T, Law CL, Izui S.
    Arthritis Rheum; 2003 Jun 01; 48(6):1612-21. PubMed ID: 12794829
    [Abstract] [Full Text] [Related]

  • 8. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions.
    Van den Eertwegh AJ, Noelle RJ, Roy M, Shepherd DM, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E.
    J Exp Med; 1993 Nov 01; 178(5):1555-65. PubMed ID: 7693849
    [Abstract] [Full Text] [Related]

  • 9. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39.
    Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ.
    J Exp Med; 1993 Nov 01; 178(5):1567-75. PubMed ID: 7693850
    [Abstract] [Full Text] [Related]

  • 10. CD40-mediated stimulation contributes to lymphocyte proliferation, antibody production, eosinophilia, and mastocytosis during an in vivo type 2 response, but is not required for T cell IL-4 production.
    Lu P, Urban JF, Zhou XD, Chen SJ, Madden K, Moorman M, Nguyen H, Morris SC, Finkelman FD, Gause WC.
    J Immunol; 1996 May 01; 156(9):3327-33. PubMed ID: 8617957
    [Abstract] [Full Text] [Related]

  • 11. The regulation of T cell-dependent antibody formation in vitro by CD40 ligand and IL-2.
    Grabstein KH, Maliszewski CR, Shanebeck K, Sato TA, Spriggs MK, Fanslow WC, Armitage RJ.
    J Immunol; 1993 Apr 15; 150(8 Pt 1):3141-7. PubMed ID: 7682232
    [Abstract] [Full Text] [Related]

  • 12. Resting B cells from autoimmune lupus-prone New Zealand Black and (New Zealand Black x New Zealand White)F1 mice are hyper-responsive to T cell-derived stimuli.
    Jongstra-Bilen J, Vukusic B, Boras K, Wither JE.
    J Immunol; 1997 Dec 15; 159(12):5810-20. PubMed ID: 9550377
    [Abstract] [Full Text] [Related]

  • 13. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells.
    Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ.
    J Immunol; 1993 Sep 01; 151(5):2497-510. PubMed ID: 8103067
    [Abstract] [Full Text] [Related]

  • 14. In vivo T-B cell interactions and cytokine-production in the spleen.
    van den Eertwegh AJ, Laman JD, Noelle RJ, Boersma WJ, Claassen E.
    Semin Immunol; 1994 Oct 01; 6(5):327-36. PubMed ID: 7532461
    [Abstract] [Full Text] [Related]

  • 15. Abrogation of pathogenic IgG autoantibody production in CD40L gene-deleted lupus-prone New Zealand Black mice.
    Pau E, Chang NH, Loh C, Lajoie G, Wither JE.
    Clin Immunol; 2011 May 01; 139(2):215-27. PubMed ID: 21414847
    [Abstract] [Full Text] [Related]

  • 16. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency.
    Ochs HD, Hollenbaugh D, Aruffo A.
    Semin Immunol; 1994 Oct 01; 6(5):337-41. PubMed ID: 7532462
    [Abstract] [Full Text] [Related]

  • 17. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice.
    Nakajima A, Hirose S, Yagita H, Okumura K.
    J Immunol; 1997 Feb 01; 158(3):1466-72. PubMed ID: 9013993
    [Abstract] [Full Text] [Related]

  • 18. Prevention and reversal of lupus in NZB/NZW mice by costimulatory blockade with adeno-associated virus-mediated gene transfer.
    Ye X, Zhu T, Bastacky S, McHale T, Li J, Xiao X.
    Arthritis Rheum; 2005 Dec 01; 52(12):3975-86. PubMed ID: 16329128
    [Abstract] [Full Text] [Related]

  • 19. The expansive role of CD40 and its ligand, gp39, in immunity.
    Foy TM, Durie FH, Noelle RJ.
    Semin Immunol; 1994 Oct 01; 6(5):259-66. PubMed ID: 7532456
    [Abstract] [Full Text] [Related]

  • 20. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM.
    Arthritis Rheum; 2005 Feb 01; 52(2):501-13. PubMed ID: 15693003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.